Mural Oncology is halting development of its lead IL-2 therapy and enacting major layoffs after its second trial failure this ...

Irish medical and pharmaceutical exports to the US have seen a surge, with a year-on-year increase above 450% in February ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Boehringer and Cue Biopharma have entered a strategic research partnership and licence agreement for the latter’s CUE-501.

J&J is projecting a $400m hit due to US tariffs in 2025, but reaffirmed its profit outlook while raising its sales forecast.

Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's.

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary cancers.

At the ESCMID Global conference in Austria, the development of climate-informed infectious disease risk management systems was discussed.

Concerns over a potential US recession this year are growing as investors assess the impact of Trump's tariff policies.

The latest trends in cell therapies indicate a growing confidence in their effectiveness, an expansion of applications beyond oncology and significant market growth potential. However, the industry ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.